Innovation meets convenience with our first homegrown recombinant monoclonal antibody to gain approval by the FDA, a significant milestone in our commitment to advancing hereditary angioedema \(HAE\) treatment. With once-monthly dosing via an autoinjector, it offers a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community around the world and continue our legacy of delivering breakthrough therapies for rare diseases. https://bit.ly/40buGTI #HAE #CSL #Biotech #Pharma #FDAApproval #HereditaryAngioedema
World Sickle Cell Day 2025
People who live with sickle cell disease cope with a debilitating condition that alters the course of their lives.
World Sickle Cell Day, June 19, is a day to raise awareness about the need for patient-focused research and innovation.
CSL's 2025 Half Year Financial Results Click here for Full Information including Webcast Recording → | Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
20 Jun
🎉 Celebrating 25 years of CSL Behring Bern! For a quarter of a century, our Bern site has played a pivotal role in CSL’s global network — delivering life-saving therapies, driving innovation, and playing a vital role in the City of Bern and beyond. We were honored to mark this milestone with CEO Paul McKenzie, members of the Global Leadership Group, the Board of Directors, and Chairman Dr. Brian McNamee, whose reflections reminded us how far we’ve come — from the integration of ZLB Bioplasma and Aventis Behring into ZLB Behring AG to becoming a cornerstone of CSL’s success. Thank you to all employees past and present, our long-serving team members, who have helped shape this legacy — and continue to build its future. https://bit.ly/4ncrGk6 #CSLBehring #Bern25Years #Impact #Innovation
18 Jun
June 19 is #WorldSickleCellDay – a good day to learn about this group of debilitating genetic conditions that impact approximately 8 million people worldwide, and about the efforts to develop much needed, innovative treatments for patients and the wider community. CSL is proud to contribute to this important work and will imminently begin enrolment in a Stage 2/3 trial. https://bit.ly/45pK4j1
18 Jun
2 Jun
Happy Pride Month! 🌈 Today and every day, we celebrate love, identity, and the power of living authentically. Here's to a world where everyone can shine as their true selves. https://bit.ly/43rcIPr #CSL #Pride #LoveIsLove
17 Jun
CSL is proud to have sponsored hackathons at Drexel University, North Carolina State University and Rochester Institute of Technology. These events brought together talented students to develop creative solutions to real-world business challenges. Hackathons are a fantastic way to foster innovation and collaboration. Our involvement included mentoring participants, judging competitions, and staffing CSL tables to discuss technology and plasma donation. These hackathons help us connect with future leaders and reinforce CSL’s culture of collaboration and innovation. We look forward to continuing our support for STEM education and community engagement. #CSL #Hackathon #STEM #Innovation #CommunityEngagement #PromisingFutures
17 Jun
The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema \(HAE\). This milestone, along with recent approvals in multiple countries around the world, reinforces our global commitment to delivering transformational innovations to HAE patients, a community we have proudly supported for over four decades. Read more: https://bit.ly/3SR5uy5. #HAE #CSL #Biotech #Pharma #FDAApproval #HereditaryAngioedema
12 Jun
Vaccination is one of the most effective and cost-effective public health interventions which has helped reduce the burden of many infectious diseases. Professor Helen Marshall AM is an international leader in vaccine research and translating this into practice and policy and she shared her vaccinology journey for the Feery Oration at #CDIC2025 . #CSLSeqirus proudly sponsors the oration in honour of Dr Brian Feery, another distinguished scientist and major contributor to public health in Australia through research in influenza, smallpox, Q Fever, and paediatric vaccines. Learn more: https://bit.ly/4jNCqlQ #Immunisation #WHO #PublicHealth
12 Jun
Superior performance starts with a mindset. At CSL, we turn imagination into action, action into results, and challenges into breakthroughs. When we ask, “How can this be better?” we follow through. When we reach beyond expectations, we celebrate. Join a team that’s committed to excellence in every step. #PromisingFutures #CSL Explore careers at CSL: https://bit.ly/44luCCv
10 Jun
By working closely with health care professionals, patient advocacy groups and research institutions, we ensure that our innovations reach the people who need them most. Our mission is clear: to provide life-saving and life-enhancing therapies to patients worldwide. Learn more about our global impact: https://bit.ly/3FNxG1R
6 Jun
It is exciting to see CSL Seqirus brand new, world-class vaccine and antivenom manufacturing facility in Melbourne coming to life. Members of the Australian Technical Advisory Group on Immunisation \(ATAGI\) recently toured the site to gain a better understanding of the facility's scale, the anticipated seasonal operations, and how CSL Seqirus would respond in the event of an influenza pandemic. Joining them were representatives from the Department of Health, Disability and Ageing, who organized the tour as part of ATAGI’s industry engagement activities. Learn more about CSL Seqirus here: https://bit.ly/4kUJ9vt #CSL #CSLSeqirus #CSLManufacturing #Manufacturing #Melbourne #ATAGI
